Eaton, C., Wells, J., Holen, I., Croucher, P., & Hamdy, F. (2004). Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Chicago-čujuhus (17. p.)Eaton, C., J. Wells, I. Holen, P. Croucher, juo F. Hamdy. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.
MLA-čujuhus (9. p.)Eaton, C., et al. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.